Congenital heart disease (CHD) represents one of the most common congenital malformations, affecting greater than 40,000 births annually in the United States, many of which require surgery during the first months of life (¹). Furthermore, postoperative mortality is now less than 2% in many centers for most lesions, and the number of adult survivors of CHD keeps increasing (²) with considerable burden related to neuromotor, cognitive, behavioral, and psychological long-term sequelae (^3,4). In 2010, the National Institutes of Health-funded Pediatric Heart Network called for randomized clinical trials (RCTs) to enhance the evidence base for novel interventions which could improve outcomes of children with CHD (⁵).